Home › Therapeutic areas › Oncology › Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (4 companies)
Companies with an active program in Diffuse Large B-Cell Lymphoma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADCT | ADC Therapeutics | Oncology | 1 | Approved | $202M | 5 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 1 | Approved | $341M | 12 |
| FHTX | Foghorn Therapeutics | Oncology | 1 | Preclinical | $111M | 4 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
No companies match.